From genes to drugs: targeted strategies for melanoma.

PubWeight™: 2.46‹?› | Rank: Top 2%

🔗 View Article (PMID 22475929)

Published in Nat Rev Cancer on April 05, 2012

Authors

Keith T Flaherty1, F Stephen Hodi, David E Fisher

Author Affiliations

1: Massachusetts General Hospital Cancer Center, 55 Fruit Street, Boston, Massachusetts 02114, USA.

Associated clinical trials:

A Phase 1 Study of Nivolumab (BMS-936558) in Subjects With Advanced or Recurrent Malignancies (MDX1106-03) | NCT00730639

Study of Pembrolizumab (MK-3475) in Participants With Progressive Locally Advanced or Metastatic Carcinoma, Melanoma, or Non-small Cell Lung Carcinoma (P07990/MK-3475-001/KEYNOTE-001) (KEYNOTE-001) | NCT01295827

Multiple Ascending Dose (MDX1105-01) (Anti-PDL1) | NCT00729664

Anti-OX40, Cyclophosphamide (CTX) and Radiation in Patients With Progressive Metastatic Prostate Cancer | NCT01303705

Temozolomide or Selumetinib in Treating Patients With Metastatic Melanoma of the Eye | NCT01143402

Safety, Tolerability and Efficacy Study of the Monoclonal Antibody, CT-011, in Patients With Metastatic Melanoma | NCT01435369

A Study of AMNN107 in the Treatment of Metastatic and/or Inoperable Melanoma Harboring a c-Kit Mutation (TEAM) | NCT01028222

Study of Nilotinib in Metastatic Melanoma With KIT Aberrations | NCT01099514

A Phase 1 Study of LY2835219 In Participants With Advanced Cancer | NCT01394016

Study of Immune Responses in Patients With Metastatic Melanoma | NCT01416844

Gamma-secretase/Notch Signalling Pathway Inhibitor RO4929097 in Combination With Cisplatin, Vinblastine, and Temozolomide in Treating Patients With Recurrent or Metastatic Melanoma | NCT01196416

Panobinostat (LBH589) in Patients With Metastatic Melanoma | NCT01065467

NCT01510444

Sorafenib Tosylate in Treating Patients With Locally Advanced, Metastatic, or Locally Recurrent Thyroid Cancer | NCT00095693

RO4929097 in Treating Patients With Stage IIIB, Stage IIIC, or Stage IV Melanoma That Can Be Removed by Surgery | NCT01216787

Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Stage IV Melanoma | NCT01120275

Dasatinib in Treating Patients With Locally Advanced or Metastatic Mucosal Melanoma, Acral Melanoma, or Vulvovaginal Melanoma That Cannot Be Removed By Surgery | NCT00700882

Dinaciclib in Treating Patients With Stage IV Melanoma | NCT00937937

Articles citing this

A landscape of driver mutations in melanoma. Cell (2012) 12.61

Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma. Nature (2014) 3.80

A novel role for microphthalmia-associated transcription factor-regulated pigment epithelium-derived factor during melanoma progression. Am J Pathol (2014) 2.61

Kinase fusions are frequent in Spitz tumours and spitzoid melanomas. Nat Commun (2014) 2.00

Phenformin enhances the therapeutic benefit of BRAF(V600E) inhibition in melanoma. Proc Natl Acad Sci U S A (2013) 1.77

A conditional zebrafish MITF mutation reveals MITF levels are critical for melanoma promotion vs. regression in vivo. J Invest Dermatol (2013) 1.74

Orphan nuclear receptor TR3 acts in autophagic cell death via mitochondrial signaling pathway. Nat Chem Biol (2013) 1.71

TORC1 suppression predicts responsiveness to RAF and MEK inhibition in BRAF-mutant melanoma. Sci Transl Med (2013) 1.67

The genetic heterogeneity and mutational burden of engineered melanomas in zebrafish models. Genome Biol (2013) 1.54

MelanomaDB: A Web Tool for Integrative Analysis of Melanoma Genomic Information to Identify Disease-Associated Molecular Pathways. Front Oncol (2013) 1.53

TERT promoter mutations in ocular melanoma distinguish between conjunctival and uveal tumours. Br J Cancer (2013) 1.38

S100 proteins in cancer. Nat Rev Cancer (2015) 1.35

HIF1α and HIF2α independently activate SRC to promote melanoma metastases. J Clin Invest (2013) 1.32

Melanoma Cell-Intrinsic PD-1 Receptor Functions Promote Tumor Growth. Cell (2015) 1.27

A meta-analysis of somatic mutations from next generation sequencing of 241 melanomas: a road map for the study of genes with potential clinical relevance. Mol Cancer Ther (2014) 1.21

Cytochromes p450 and skin cancer: role of local endocrine pathways. Anticancer Agents Med Chem (2014) 1.20

Managing drug resistance in cancer: lessons from HIV therapy. Nat Rev Cancer (2012) 1.19

Novel vitamin D hydroxyderivatives inhibit melanoma growth and show differential effects on normal melanocytes. Anticancer Res (2012) 1.18

Pathways and therapeutic targets in melanoma. Oncotarget (2014) 1.17

WNT5A enhances resistance of melanoma cells to targeted BRAF inhibitors. J Clin Invest (2014) 1.16

Novel roles for the MiTF/TFE family of transcription factors in organelle biogenesis, nutrient sensing, and energy homeostasis. Cell Mol Life Sci (2014) 1.14

The dynamic control of signal transduction networks in cancer cells. Nat Rev Cancer (2015) 1.09

Extracellular vesicles - biomarkers and effectors of the cellular interactome in cancer. Front Pharmacol (2013) 1.09

Low-copy piggyBac transposon mutagenesis in mice identifies genes driving melanoma. Proc Natl Acad Sci U S A (2013) 1.04

Isolation and molecular characterization of circulating melanoma cells. Cell Rep (2014) 1.02

Lack of SF3B1 R625 mutations in cutaneous melanoma. Diagn Pathol (2013) 1.00

Targeting survivin in cancer: novel drug development approaches. BioDrugs (2014) 0.98

MITF in melanoma: mechanisms behind its expression and activity. Cell Mol Life Sci (2014) 0.97

BRAF Inhibition Stimulates Melanoma-Associated Macrophages to Drive Tumor Growth. Clin Cancer Res (2015) 0.95

Activation of Wnt/β-catenin signaling increases apoptosis in melanoma cells treated with trail. PLoS One (2013) 0.95

A tale of two approaches: complementary mechanisms of cytotoxic and targeted therapy resistance may inform next-generation cancer treatments. Carcinogenesis (2013) 0.94

Melanoma stem cells and metastasis: mimicking hematopoietic cell trafficking? Lab Invest (2013) 0.92

A highly recurrent RPS27 5'UTR mutation in melanoma. Oncotarget (2014) 0.92

Insights into the Transforming Growth Factor-β Signaling Pathway in Cutaneous Melanoma. Ann Dermatol (2013) 0.92

Computational approach for designing tumor homing peptides. Sci Rep (2013) 0.92

Pro-survival role of MITF in melanoma. J Invest Dermatol (2014) 0.91

The next steps in next-gen sequencing of cancer genomes. J Clin Invest (2015) 0.91

The Conundrum of Genetic "Drivers" in Benign Conditions. J Natl Cancer Inst (2016) 0.90

Development of potent autophagy inhibitors that sensitize oncogenic BRAF V600E mutant melanoma tumor cells to vemurafenib. Autophagy (2014) 0.89

UV signaling pathways within the skin. J Invest Dermatol (2014) 0.88

Signaling Pathways in Melanogenesis. Int J Mol Sci (2016) 0.87

Next generation sequencing of exceptional responders with BRAF-mutant melanoma: implications for sensitivity and resistance. BMC Cancer (2015) 0.85

Impact of MAPK Pathway Activation in BRAF(V600) Melanoma on T Cell and Dendritic Cell Function. Front Immunol (2013) 0.85

Phenotypic diversity of patient-derived melanoma populations in stem cell medium. Lab Invest (2015) 0.84

Insulin-like growth factor system in cancer: novel targeted therapies. Biomed Res Int (2015) 0.84

Rare Tumors in Children: Progress Through Collaboration. J Clin Oncol (2015) 0.83

Functional profiling of live melanoma samples using a novel automated platform. PLoS One (2012) 0.83

Brain neoplasms and coagulation-lessons from heterogeneity. Rambam Maimonides Med J (2014) 0.83

A DNA vaccine targeting p42.3 induces protective antitumor immunity via eliciting cytotoxic CD8+T lymphocytes in a murine melanoma model. Hum Vaccin Immunother (2013) 0.82

Vesicular stomatitis virus variants selectively infect and kill human melanomas but not normal melanocytes. J Virol (2013) 0.82

Multiple Molecular Pathways in Melanomagenesis: Characterization of Therapeutic Targets. Front Oncol (2015) 0.82

Hydrogels and scaffolds for immunomodulation. Adv Mater (2014) 0.82

TRIM16 inhibits proliferation and migration through regulation of interferon beta 1 in melanoma cells. Oncotarget (2014) 0.82

Integrated pathway and epistasis analysis reveals interactive effect of genetic variants at TERF1 and AFAP1L2 loci on melanoma risk. Int J Cancer (2015) 0.82

Gene expression analyses of primary melanomas reveal CTHRC1 as an important player in melanoma progression. Oncotarget (2016) 0.81

Malignant melanoma and melanocortin 1 receptor. Biochemistry (Mosc) (2013) 0.81

Parthenolide induces MITF-M downregulation and senescence in patient-derived MITF-Mhigh melanoma cell populations. Oncotarget (2016) 0.81

Targeting multiple key signaling pathways in melanoma using leelamine. Mol Cancer Ther (2014) 0.81

Overexpression of Mcl-1 confers resistance to BRAFV600E inhibitors alone and in combination with MEK1/2 inhibitors in melanoma. Oncotarget (2015) 0.81

Fisetin, a phytochemical, potentiates sorafenib-induced apoptosis and abrogates tumor growth in athymic nude mice implanted with BRAF-mutated melanoma cells. Oncotarget (2015) 0.80

YY1 regulates melanoma tumorigenesis through a miR-9 ~ RYBP axis. J Exp Clin Cancer Res (2015) 0.80

NUAK2 Amplification Coupled with PTEN Deficiency Promotes Melanoma Development via CDK Activation. Cancer Res (2015) 0.79

Melanoma: oncogenic drivers and the immune system. Ann Transl Med (2015) 0.78

Phenotyping of human melanoma cells reveals a unique composition of receptor targets and a subpopulation co-expressing ErbB4, EPO-R and NGF-R. PLoS One (2014) 0.78

YAP and the drug resistance highway. Nat Genet (2015) 0.77

Lentivirus-induced 'Smart' dendritic cells: Pharmacodynamics and GMP-compliant production for immunotherapy against TRP2-positive melanoma. Gene Ther (2015) 0.77

The involvement of mutant Rac1 in the formation of invadopodia in cultured melanoma cells. Exp Cell Res (2016) 0.76

Establishment of HRAS(G12V) transgenic medaka as a stable tumor model for in vivo screening of anticancer drugs. PLoS One (2013) 0.76

BRAFV600E immunopositive melanomas show low frequency of heterogeneity and association with epithelioid tumor cells: a STROBE-compliant article. Medicine (Baltimore) (2014) 0.76

Euphorbia fischeriana Steud inhibits malignant melanoma via modulation of the phosphoinositide-3-kinase/Akt signaling pathway. Exp Ther Med (2016) 0.76

Butein inhibits metastatic behavior in mouse melanoma cells through VEGF expression and translation-dependent signaling pathway regulation. BMC Complement Altern Med (2015) 0.76

Recombinant adeno-associated virus serotype 6 efficiently transduces primary human melanocytes. PLoS One (2013) 0.75

Dermatology: Where are We Coming from and Where are We Going to? Front Med (Lausanne) (2014) 0.75

Extracutaneous melanomas: a primer for the radiologist. Insights Imaging (2015) 0.75

Gomisin N Inhibits Melanogenesis through Regulating the PI3K/Akt and MAPK/ERK Signaling Pathways in Melanocytes. Int J Mol Sci (2017) 0.75

Adaptive Resistance to Immunotherapy Directed Against p53 Can be Overcome by Global Expression of Tumor-Antigens in Dendritic Cells. Front Oncol (2014) 0.75

MGDB: a comprehensive database of genes involved in melanoma. Database (Oxford) (2015) 0.75

Malignant Melanoma. Healthcare (Basel) (2013) 0.75

Eradicating tumor drug resistance at its YAP-biomechanical roots. EMBO J (2015) 0.75

Assessing Combinational Drug Efficacy in Cancer Cells by Using Image-based Dynamic Response Analysis. Cancer Inform (2016) 0.75

Targeting BMK1 Impairs the Drug Resistance to Combined Inhibition of BRAF and MEK1/2 in Melanoma. Sci Rep (2017) 0.75

Deep-proteome mapping of WM-266-4 human metastatic melanoma cells: From oncogenic addiction to druggable targets. PLoS One (2017) 0.75

Detecting human melanoma cell re-differentiation following BRAF or heat shock protein 90 inhibition using photoacoustic and magnetic resonance imaging. Sci Rep (2017) 0.75

Genetic variants in the metzincin metallopeptidase family genes predict melanoma survival. Mol Carcinog (2017) 0.75

Biomarker Accessible and Chemically Addressable Mechanistic Subtypes of BRAF Melanoma. Cancer Discov (2017) 0.75

Aberrant expression of kallikrein-related peptidase 7 is correlated to human melanoma aggressiveness by stimulating cell migration and invasion. Mol Oncol (2017) 0.75

Zebrafish as a Model Organism for the Development of Drugs for Skin Cancer. Int J Mol Sci (2017) 0.75

DAN (NBL1) promotes collective neural crest migration by restraining uncontrolled invasion. J Cell Biol (2017) 0.75

Anti-Melanoma Activities of Haspin Inhibitor CHR-6494 Deployed as a Single Agent or in a Synergistic Combination with MEK Inhibitor. J Cancer (2017) 0.75

Articles cited by this

(truncated to the top 100)

Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med (2010) 67.34

Mutations of the BRAF gene in human cancer. Nature (2002) 65.42

Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med (2011) 45.46

Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med (2010) 36.57

Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med (2011) 26.90

BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res (2004) 21.36

Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med (2000) 19.81

Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature (2010) 18.69

Enhancement of antitumor immunity by CTLA-4 blockade. Science (1996) 17.94

Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF. Cell (2010) 17.48

Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity. Proc Natl Acad Sci U S A (2008) 17.41

RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF. Nature (2010) 17.31

Distinct sets of genetic alterations in melanoma. N Engl J Med (2005) 17.26

BRAF mutation predicts sensitivity to MEK inhibition. Nature (2005) 17.14

BRAFE600-associated senescence-like cell cycle arrest of human naevi. Nature (2005) 16.87

RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth. Nature (2010) 15.63

Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma. Nature (2005) 15.28

COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. Nature (2010) 14.62

A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science (1991) 14.57

A cell cycle regulator potentially involved in genesis of many tumor types. Science (1994) 13.00

Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K. Cancer Cell (2010) 12.50

Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc Natl Acad Sci U S A (2002) 12.39

Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci U S A (1993) 11.95

Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat Med (1998) 11.03

RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E). Nature (2011) 10.77

Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc Natl Acad Sci U S A (2003) 10.71

Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J Clin Oncol (2000) 9.70

Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol (2003) 8.95

Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor. Proc Natl Acad Sci U S A (1994) 8.92

Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study. Lancet Oncol (2009) 8.68

Frequent somatic mutations of GNAQ in uveal melanoma and blue naevi. Nature (2008) 8.42

Braf(V600E) cooperates with Pten loss to induce metastatic melanoma. Nat Genet (2009) 7.81

Somatic activation of KIT in distinct subtypes of melanoma. J Clin Oncol (2006) 7.76

Induction of tumor immunity by removing CD25+CD4+ T cells: a common basis between tumor immunity and autoimmunity. J Immunol (1999) 7.60

Frequent mutation of BAP1 in metastasizing uveal melanomas. Science (2010) 7.47

TNF/TNFR family members in costimulation of T cell responses. Annu Rev Immunol (2005) 7.44

Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejection. Proc Natl Acad Sci U S A (1994) 6.93

RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors. N Engl J Med (2012) 6.93

Discovery and development of sorafenib: a multikinase inhibitor for treating cancer. Nat Rev Drug Discov (2006) 6.88

Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens. Science (1994) 6.73

MEK1 mutations confer resistance to MEK and B-RAF inhibition. Proc Natl Acad Sci U S A (2009) 6.58

The tyrosinase gene codes for an antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J Exp Med (1993) 6.47

Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma. J Clin Oncol (2009) 6.44

The central role of CD4(+) T cells in the antitumor immune response. J Exp Med (1998) 6.02

Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phase II study. Ann Oncol (2010) 5.91

Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2-restricted tumor infiltrating lymphocytes. J Exp Med (1994) 5.67

A p16INK4a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma. Science (1995) 5.46

Model predicting survival in stage I melanoma based on tumor progression. J Natl Cancer Inst (1989) 5.28

Cloned dendritic cells can present exogenous antigens on both MHC class I and class II molecules. J Immunol (1997) 5.06

A new gene coding for a differentiation antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J Exp Med (1994) 5.03

Melanoma whole-exome sequencing identifies (V600E)B-RAF amplification-mediated acquired B-RAF inhibitor resistance. Nat Commun (2012) 4.94

Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis. Br J Cancer (2006) 4.93

PTEN loss confers BRAF inhibitor resistance to melanoma cells through the suppression of BIM expression. Cancer Res (2011) 4.80

Antigen-specific inhibition of effector T cell function in humans after injection of immature dendritic cells. J Exp Med (2001) 4.78

Oncogenic Braf induces melanocyte senescence and melanoma in mice. Cancer Cell (2009) 4.76

The melanocyte differentiation program predisposes to metastasis after neoplastic transformation. Nat Genet (2005) 4.70

MITF: master regulator of melanocyte development and melanoma oncogene. Trends Mol Med (2006) 4.60

Embryonic and tumorigenic pathways converge via Nodal signaling: role in melanoma aggressiveness. Nat Med (2006) 4.54

V599EB-RAF is an oncogene in melanocytes. Cancer Res (2004) 4.49

Mechanisms of disease: Oncogene addiction--a rationale for molecular targeting in cancer therapy. Nat Clin Pract Oncol (2006) 4.47

Suppression of BRAF(V599E) in human melanoma abrogates transformation. Cancer Res (2003) 4.28

Anti-cytotoxic T-lymphocyte antigen-4 antibody: the first in an emerging class of immunomodulatory antibodies for cancer treatment. J Clin Oncol (2008) 4.23

Demonstration of a genetic therapeutic index for tumors expressing oncogenic BRAF by the kinase inhibitor SB-590885. Cancer Res (2006) 4.20

AZD6244 (ARRY-142886), a potent inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase 1/2 kinases: mechanism of action in vivo, pharmacokinetic/pharmacodynamic relationship, and potential for combination in preclinical models. Mol Cancer Ther (2007) 4.16

Analysis of the tyrosine kinome in melanoma reveals recurrent mutations in ERBB4. Nat Genet (2009) 3.80

Deregulated Akt3 activity promotes development of malignant melanoma. Cancer Res (2004) 3.80

Genetic interaction between NRAS and BRAF mutations and PTEN/MMAC1 inactivation in melanoma. J Invest Dermatol (2004) 3.80

Differences in dendritic cells stimulated in vivo by tumors engineered to secrete granulocyte-macrophage colony-stimulating factor or Flt3-ligand. Cancer Res (2000) 3.79

Bcl2 regulation by the melanocyte master regulator Mitf modulates lineage survival and melanoma cell viability. Cell (2002) 3.72

BRAF mutations are sufficient to promote nevi formation and cooperate with p53 in the genesis of melanoma. Curr Biol (2005) 3.68

Targeting cytotoxic T-lymphocyte antigen-4 (CTLA-4): a novel strategy for the treatment of melanoma and other malignancies. Cancer (2007) 3.67

B-RAF is a therapeutic target in melanoma. Oncogene (2004) 3.61

CD4+CD25+ T regulatory cells dependent on ICOS promote regulation of effector cells in the prediabetic lesion. J Exp Med (2004) 3.57

A SUMOylation-defective MITF germline mutation predisposes to melanoma and renal carcinoma. Nature (2011) 3.53

KIT as a therapeutic target in metastatic melanoma. JAMA (2011) 3.49

Complete molecular remissions induced by patient-specific vaccination plus granulocyte-monocyte colony-stimulating factor against lymphoma. Nat Med (1999) 3.18

Major response to imatinib mesylate in KIT-mutated melanoma. J Clin Oncol (2008) 3.16

c-Kit triggers dual phosphorylations, which couple activation and degradation of the essential melanocyte factor Mi. Genes Dev (2000) 3.13

Immune and clinical responses in patients with metastatic melanoma to CD34(+) progenitor-derived dendritic cell vaccine. Cancer Res (2001) 3.01

A mutated beta-catenin gene encodes a melanoma-specific antigen recognized by tumor infiltrating lymphocytes. J Exp Med (1996) 2.99

Disruption of the MMAC1/PTEN gene by deletion or mutation is a frequent event in malignant melanoma. Cancer Res (1997) 2.98

A novel recurrent mutation in MITF predisposes to familial and sporadic melanoma. Nature (2011) 2.96

Inhibition of myeloid cell differentiation in cancer: the role of reactive oxygen species. J Leukoc Biol (2003) 2.94

Clinical activity and immune modulation in cancer patients treated with CP-870,893, a novel CD40 agonist monoclonal antibody. J Clin Oncol (2007) 2.92

Sustained expansion of NKT cells and antigen-specific T cells after injection of alpha-galactosyl-ceramide loaded mature dendritic cells in cancer patients. J Exp Med (2005) 2.90

A new family of genes coding for an antigen recognized by autologous cytolytic T lymphocytes on a human melanoma. J Exp Med (1995) 2.88

Examination of mutations in BRAF, NRAS, and PTEN in primary cutaneous melanoma. J Invest Dermatol (2006) 2.87

Critical role of CDK2 for melanoma growth linked to its melanocyte-specific transcriptional regulation by MITF. Cancer Cell (2004) 2.80

Lymphoproliferation in CTLA-4-deficient mice is mediated by costimulation-dependent activation of CD4+ T cells. Immunity (1997) 2.72

Clinical and immunologic results of a randomized phase II trial of vaccination using four melanoma peptides either administered in granulocyte-macrophage colony-stimulating factor in adjuvant or pulsed on dendritic cells. J Clin Oncol (2003) 2.67

Immunological and clinical responses in metastatic renal cancer patients vaccinated with tumor RNA-transfected dendritic cells. Cancer Res (2003) 2.62

Increased serum concentration of angiogenic factors in malignant melanoma patients correlates with tumor progression and survival. J Clin Oncol (2001) 2.58

BRAF silencing by short hairpin RNA or chemical blockade by PLX4032 leads to different responses in melanoma and thyroid carcinoma cells. Mol Cancer Res (2008) 2.57

KIT gene mutations and copy number in melanoma subtypes. Clin Cancer Res (2008) 2.57

Genome-wide loss of heterozygosity and copy number analysis in melanoma using high-density single-nucleotide polymorphism arrays. Cancer Res (2007) 2.51

Elucidating the autoimmune and antitumor effector mechanisms of a treatment based on cytotoxic T lymphocyte antigen-4 blockade in combination with a B16 melanoma vaccine: comparison of prophylaxis and therapy. J Exp Med (2001) 2.46

Chromosomal gains and losses in primary cutaneous melanomas detected by comparative genomic hybridization. Cancer Res (1998) 2.44

New insight into BRAF mutations in cancer. Curr Opin Genet Dev (2007) 2.40

Phase II, open-label, single-arm trial of imatinib mesylate in patients with metastatic melanoma harboring c-Kit mutation or amplification. J Clin Oncol (2011) 2.38

Activated B-RAF is an Hsp90 client protein that is targeted by the anticancer drug 17-allylamino-17-demethoxygeldanamycin. Cancer Res (2005) 2.34

Articles by these authors

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med (2012) 52.99

Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res (2009) 24.11

Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med (2013) 18.08

Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma. Nature (2005) 15.28

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. N Engl J Med (2015) 14.71

High-throughput oncogene mutation profiling in human cancer. Nat Genet (2007) 12.68

Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol (2014) 9.86

Integrative analysis of the melanoma transcriptome. Genome Res (2010) 8.46

Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N Engl J Med (2015) 7.51

Modeling genomic diversity and tumor dependency in malignant melanoma. Cancer Res (2008) 5.95

Chromatin structure analyses identify miRNA promoters. Genes Dev (2008) 5.40

Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial. Lancet Oncol (2012) 5.32

High-throughput mapping of the chromatin structure of human promoters. Nat Biotechnol (2007) 5.24

Improved endpoints for cancer immunotherapy trials. J Natl Cancer Inst (2010) 5.23

Central role of p53 in the suntan response and pathologic hyperpigmentation. Cell (2007) 4.75

Selective BRAFV600E inhibition enhances T-cell recognition of melanoma without affecting lymphocyte function. Cancer Res (2010) 4.71

MITF: master regulator of melanocyte development and melanoma oncogene. Trends Mol Med (2006) 4.60

BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma. Clin Cancer Res (2013) 4.28

Malignant melanoma: genetics and therapeutics in the genomic era. Genes Dev (2006) 4.24

Bcl2 regulation by the melanocyte master regulator Mitf modulates lineage survival and melanoma cell viability. Cell (2002) 3.72

BRAF mutations are sufficient to promote nevi formation and cooperate with p53 in the genesis of melanoma. Curr Biol (2005) 3.68

Oncogenic BRAF regulates oxidative metabolism via PGC1α and MITF. Cancer Cell (2013) 3.63

Double-blind randomized phase II study of the combination of sorafenib and dacarbazine in patients with advanced melanoma: a report from the 11715 Study Group. J Clin Oncol (2008) 3.58

Hepatotoxicity with combination of vemurafenib and ipilimumab. N Engl J Med (2013) 3.51

Melanocyte biology and skin pigmentation. Nature (2007) 3.43

Activating mutations of the noonan syndrome-associated SHP2/PTPN11 gene in human solid tumors and adult acute myelogenous leukemia. Cancer Res (2004) 3.20

Major response to imatinib mesylate in KIT-mutated melanoma. J Clin Oncol (2008) 3.16

Mechanisms of hair graying: incomplete melanocyte stem cell maintenance in the niche. Science (2004) 3.12

CTLA-4 and PD-1/PD-L1 blockade: new immunotherapeutic modalities with durable clinical benefit in melanoma patients. Clin Cancer Res (2013) 3.02

A novel recurrent mutation in MITF predisposes to familial and sporadic melanoma. Nature (2011) 2.96

Critical role of CDK2 for melanoma growth linked to its melanocyte-specific transcriptional regulation by MITF. Cancer Cell (2004) 2.80

GOLPH3 modulates mTOR signalling and rapamycin sensitivity in cancer. Nature (2009) 2.77

Molecular pathways: next-generation immunotherapy--inhibiting programmed death-ligand 1 and programmed death-1. Clin Cancer Res (2012) 2.68

The activation of MAPK in melanoma cells resistant to BRAF inhibition promotes PD-L1 expression that is reversible by MEK and PI3K inhibition. Clin Cancer Res (2012) 2.63

Melanoma: from mutations to medicine. Genes Dev (2012) 2.59

KIT gene mutations and copy number in melanoma subtypes. Clin Cancer Res (2008) 2.57

Vaccination with irradiated autologous tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor augments antitumor immunity in some patients with metastatic non-small-cell lung carcinoma. J Clin Oncol (2003) 2.36

An ultraviolet-radiation-independent pathway to melanoma carcinogenesis in the red hair/fair skin background. Nature (2012) 2.35

Defining the critical hurdles in cancer immunotherapy. J Transl Med (2011) 2.32

Microphthalamia-associated transcription factor: a critical regulator of pigment cell development and survival. Oncogene (2003) 2.19

Outcomes of patients with metastatic melanoma treated with immunotherapy prior to or after BRAF inhibitors. Cancer (2014) 2.12

Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin. J Clin Oncol (2013) 2.11

Topical drug rescue strategy and skin protection based on the role of Mc1r in UV-induced tanning. Nature (2006) 2.09

Key roles for transforming growth factor beta in melanocyte stem cell maintenance. Cell Stem Cell (2010) 2.06

Development of ipilimumab: a novel immunotherapeutic approach for the treatment of advanced melanoma. Ann N Y Acad Sci (2013) 2.03

Beta-catenin-induced melanoma growth requires the downstream target Microphthalmia-associated transcription factor. J Cell Biol (2002) 2.00

An oncogenic role for ETV1 in melanoma. Cancer Res (2010) 1.94

TFE3 fusions activate MET signaling by transcriptional up-regulation, defining another class of tumors as candidates for therapeutic MET inhibition. Cancer Res (2007) 1.93

Ipilimumab and its toxicities: a multidisciplinary approach. Oncologist (2013) 1.91

MLANA/MART1 and SILV/PMEL17/GP100 are transcriptionally regulated by MITF in melanocytes and melanoma. Am J Pathol (2003) 1.90

Therapy-induced antibodies to MHC class I chain-related protein A antagonize immune suppression and stimulate antitumor cytotoxicity. Proc Natl Acad Sci U S A (2006) 1.88

Melanoma of unknown primary: experience at Massachusetts General Hospital and Dana-Farber Cancer Institute. Melanoma Res (2005) 1.87

Intronic miR-211 assumes the tumor suppressive function of its host gene in melanoma. Mol Cell (2010) 1.86

Modulation of T-cell activation by malignant melanoma initiating cells. Cancer Res (2010) 1.83

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. N Engl J Med (2015) 1.80

NFATc2-mediated repression of cyclin-dependent kinase 4 expression. Mol Cell (2002) 1.79

UV and pigmentation: molecular mechanisms and social controversies. Pigment Cell Melanoma Res (2008) 1.78

A polymorphism in IRF4 affects human pigmentation through a tyrosinase-dependent MITF/TFAP2A pathway. Cell (2013) 1.75

Imatinib targeting of KIT-mutant oncoprotein in melanoma. Clin Cancer Res (2008) 1.73

Cloning of an Alpha-TFEB fusion in renal tumors harboring the t(6;11)(p21;q13) chromosome translocation. Proc Natl Acad Sci U S A (2003) 1.73

BCL2A1 is a lineage-specific antiapoptotic melanoma oncogene that confers resistance to BRAF inhibition. Proc Natl Acad Sci U S A (2013) 1.72

Pycnodysostosis: role and regulation of cathepsin K in osteoclast function and human disease. Curr Mol Med (2002) 1.69

Reversal of in situ T-cell exhaustion during effective human antileukemia responses to donor lymphocyte infusion. Blood (2013) 1.67

Patterns of onset and resolution of immune-related adverse events of special interest with ipilimumab: detailed safety analysis from a phase 3 trial in patients with advanced melanoma. Cancer (2013) 1.65

Transcriptional regulation of the melanoma prognostic marker melastatin (TRPM1) by MITF in melanocytes and melanoma. Cancer Res (2004) 1.64

Anti-PD-1-Related Pneumonitis during Cancer Immunotherapy. N Engl J Med (2015) 1.64

Application of protein microarrays for multiplexed detection of antibodies to tumor antigens in breast cancer. J Proteome Res (2008) 1.63

Nuclear factor of activated T cells c1 induces osteoclast-associated receptor gene expression during tumor necrosis factor-related activation-induced cytokine-mediated osteoclastogenesis. J Biol Chem (2005) 1.62

Regulation of MITF stability by the USP13 deubiquitinase. Nat Commun (2011) 1.62

Control of melanocyte differentiation by a MITF-PDE4D3 homeostatic circuit. Genes Dev (2010) 1.61

Vaccination with irradiated, autologous melanoma cells engineered to secrete granulocyte-macrophage colony-stimulating factor by adenoviral-mediated gene transfer augments antitumor immunity in patients with metastatic melanoma. J Clin Oncol (2003) 1.61

Transdifferentiation of the retina into pigmented cells in ocular retardation mice defines a new function of the homeodomain gene Chx10. Development (2004) 1.58

Renal carcinomas with the t(6;11)(p21;q12): clinicopathologic features and demonstration of the specific alpha-TFEB gene fusion by immunohistochemistry, RT-PCR, and DNA PCR. Am J Surg Pathol (2005) 1.54

Developing a common language for tumor response to immunotherapy: immune-related response criteria using unidimensional measurements. Clin Cancer Res (2013) 1.53

A single-arm, open-label, expanded access study of vemurafenib in patients with metastatic melanoma in the United States. Cancer J (2014) 1.51

Biology and clinical relevance of the micropthalmia family of transcription factors in human cancer. J Clin Oncol (2011) 1.47

The Society for Immunotherapy of Cancer consensus statement on tumour immunotherapy for the treatment of cutaneous melanoma. Nat Rev Clin Oncol (2013) 1.46

Melanoma, version 2.2013: featured updates to the NCCN guidelines. J Natl Compr Canc Netw (2013) 1.44

Long-lived antitumor CD8+ lymphocytes for adoptive therapy generated using an artificial antigen-presenting cell. Clin Cancer Res (2007) 1.44

Mutation-driven drug development in melanoma. Curr Opin Oncol (2010) 1.43

c-Met expression is regulated by Mitf in the melanocyte lineage. J Biol Chem (2006) 1.42

Oncogenic MITF dysregulation in clear cell sarcoma: defining the MiT family of human cancers. Cancer Cell (2006) 1.41

Sumoylation of MITF and its related family members TFE3 and TFEB. J Biol Chem (2004) 1.40

Establishment of antitumor memory in humans using in vitro-educated CD8+ T cells. Sci Transl Med (2011) 1.37

Melanoma. J Natl Compr Canc Netw (2009) 1.37

Genomic analysis of the Microphthalmia locus and identification of the MITF-J/Mitf-J isoform. Gene (2005) 1.35

Enhancing the clinical activity of granulocyte-macrophage colony-stimulating factor-secreting tumor cell vaccines. Immunol Rev (2008) 1.34

How sunlight causes melanoma. Curr Oncol Rep (2010) 1.34

A new era: melanoma genetics and therapeutics. J Pathol (2010) 1.32

Lineage-specific transcriptional regulation of DICER by MITF in melanocytes. Cell (2010) 1.31

Identification of tumor-associated antigens in chronic lymphocytic leukemia by SEREX. Blood (2002) 1.31

Comparison of five antibodies as markers in the diagnosis of melanoma in cytologic preparations. Am J Clin Pathol (2002) 1.30

When progressive disease does not mean treatment failure: reconsidering the criteria for progression. J Natl Cancer Inst (2012) 1.28

Efficacy and safety of retreatment with ipilimumab in patients with pretreated advanced melanoma who progressed after initially achieving disease control. Clin Cancer Res (2013) 1.23

SKI activates Wnt/beta-catenin signaling in human melanoma. Cancer Res (2003) 1.22

Phosphatase-dependent and -independent functions of Shp2 in neural crest cells underlie LEOPARD syndrome pathogenesis. Dev Cell (2010) 1.22

Clinical activity of ipilimumab for metastatic uveal melanoma: a retrospective review of the Dana-Farber Cancer Institute, Massachusetts General Hospital, Memorial Sloan-Kettering Cancer Center, and University Hospital of Lausanne experience. Cancer (2013) 1.22

Pharmacologic suppression of MITF expression via HDAC inhibitors in the melanocyte lineage. Pigment Cell Melanoma Res (2008) 1.21